Lord, Abbett & Co. LLC Seagen Inc. Transaction History

Lord, Abbett & Co. LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $97.6 Million - $130 Million	-721,653 Reduced 97.1%	21,549 $2.95 Million
Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $72.2 Million - $119 Million	663,578 Added 833.39%	743,202 $132 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $445,547 - $587,991	-3,725 Reduced 4.47%	79,624 $11.5 Million
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $622,460 - $833,294	4,366 Added 5.53%	83,349 $12.9 Million
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $478,204 - $570,085	3,357 Added 4.44%	78,983 $13.4 Million

Q2 2021 Aug 11, 2021	BUY	$135.08 - $161.1 $1.63 Million - $1.94 Million	12,043 Added 18.94%	75,626 $11.9 Million
Q1 2021 May 11, 2021	SELL	$137.51 - $190.8 $43 Million - $59.6 Million	-312,489 Reduced 83.09%	63,583 $8.83 Million
Q4 2020 Feb 09, 2021	BUY	$164.63 - $211.93 $61.9 Million - $79.7 Million	376,072 New	376,072 $65.9 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.